Fosbretabulin for the treatment of anaplastic thyroid cancer

被引：1
|
作者：
Granata, Roberta [1 ]
Locati, Laura D. [1 ]
Licitra, Lisa [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Milan, Italy
来源：
FUTURE ONCOLOGY | 2014年 / 10卷 / 13期
关键词：
anaplastic thyroid cancer; fosbretabulin; tubulin-binding agent; COMBRETASTATIN A-4 PHOSPHATE; A4; PHOSPHATE; PHASE-II; TRIAL; AGENT; PATHOGENESIS; MANAGEMENT; CARCINOMA; SCHEDULE;
D O I：
10.2217/FON.14.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fosbretabulin tromethamine is a vascular disrupting agent, which is a type of drug that is designed to damage the vasculature (blood vessels) of cancer tumors, causing central necrosis. This drug showed activity against anaplastic thyroid cancer that was demonstrated in orthotopic xenograft models as well as in Phase I/II trials with or without carboplatin and paclitaxel combination therapy. In all of these studies, fosbretabulin was well tolerated.
引用
收藏
页码：2015 / 2021
页数：7
相关论文
共 50 条
  • [1] Fosbretabulin tromethamine in the treatment of thyroid cancer
    Krajewska, Jolanta
    Jarzab, Barbara
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (05): : 555 - 561
  • [2] Treatment Outcomes in Anaplastic Thyroid Cancer
    Corrigan, Kelsey L.
    Williamson, Hannah
    Elliott Range, Danielle
    Niedzwiecki, Donna
    Brizel, David M.
    Mowery, Yvonne M.
    JOURNAL OF THYROID RESEARCH, 2019, 2019
  • [3] Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma
    Doroshow, Deborah Blythe
    Deshpande, Hari Anant
    Remick, Scot C.
    Bhatia, Aarti K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma
    Sosa, Julie A.
    Elisei, Rossella
    Jarzab, Barbara
    Balkissoon, Jai
    Lu, Shiao-ping
    Bal, Chandrasekhar
    Marur, Shanthi
    Gramza, Ann
    Ben Yosef, Rami
    Gitlitz, Barbara
    Haugen, Bryan R.
    Ondrey, Frank
    Lu, Charles
    Karandikar, S. M.
    Khuri, Fadlo
    Licitra, Lisa
    Remick, Scot C.
    THYROID, 2014, 24 (02) : 232 - 240
  • [5] New combination treatment for anaplastic thyroid cancer
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2013, 14 (07): : E256 - E256
  • [6] What is the best treatment for Anaplastic Thyroid Cancer?
    Al-Mulki, Kareem
    Smith, Richard V.
    LARYNGOSCOPE, 2023, 133 (09): : 2044 - 2045
  • [7] Anaplastic thyroid cancer: multimodal treatment results
    Taissoun Aslan, Zaki Antonio
    Granados-Garcia, Martin
    Luna-Ortiz, Kuauhyama
    Javier Guerrero-Huerta, Francisco
    Gomez-Pedraza, Antonio
    Namendys-Silva, Silvio A.
    Meneses-Garcia, Abelardo
    Maria Ordonez-Mosquera, Juliana
    ECANCERMEDICALSCIENCE, 2014, 8
  • [8] Treatment outcomes of radiotherapy for anaplastic thyroid cancer
    Park, Jong Won
    Choi, Seo Hee
    Yoon, Hong In
    Lee, Jeongshim
    Kim, Tae Hyung
    Kim, Jun Won
    Lee, Ik Jae
    RADIATION ONCOLOGY JOURNAL, 2018, 36 (02): : 103 - 113
  • [9] Anaplastic thyroid cancer: prevalence, diagnosis and treatment
    Chiacchio, S.
    Lorenzoni, A.
    Boni, G.
    Rubello, D.
    Elisei, R.
    Mariani, G.
    MINERVA ENDOCRINOLOGICA, 2008, 33 (04) : 341 - 357
  • [10] Marginal treatment benefit in anaplastic thyroid cancer
    Haymart, Megan R.
    Banerjee, Mousumi
    Yin, Huiying
    Worden, Francis
    Griggs, Jennifer J.
    CANCER, 2013, 119 (17) : 3133 - 3139
12345